Immune checkpoint inhibitors targeting the programmed cell death-1(PD-1)protein significantly improve survival in patients with advanced non-small-cell lung cancer(NSCLC),but its impact on early-stage ground-glass opa...Immune checkpoint inhibitors targeting the programmed cell death-1(PD-1)protein significantly improve survival in patients with advanced non-small-cell lung cancer(NSCLC),but its impact on early-stage ground-glass opacity(GGO)lesions remains unclear.This is a single-arm,phase II trial(NCT04026841)using Simon’s optimal two-stage design,of which 4 doses of sintilimab(200 mg per 3 weeks)were administrated in 36 enrolled multiple primary lung cancer(MPLC)patients with persistent high-risk(Lung-RADS category 4 or had progressed within 6 months)GGOs.The primary endpoint was objective response rate(ORR).T/B/NK-cell subpopulations,TCR-seq,cytokines,exosomal RNA,and multiplexed immunohistochemistry(mIHC)were monitored and compared between responders and non-responders.Finally,two intent-to-treat(ITT)lesions(pure-GGO or GGO-predominant)showed responses(ORR:5.6%,2/36),and no patients had progressive disease(PD).No grade 3-5 TRAEs occurred.The total response rate considering two ITT lesions and three non-intent-to-treat(NITT)lesions(pure-solid or solid-predominant)was 13.9%(5/36).The proportion of CD8^(+)T cells,the ratio of CD8^(+)/CD4^(+),and the TCR clonality value were significantly higher in the peripheral blood of responders before treatment and decreased over time.Correspondingly,the mIHC analysis showed more CD8^(+)T cells infiltrated in responders.Besides,responders’cytokine concentrations of EGF and CTLA-4 increased during treatment.The exosomal expression of fatty acid metabolism and oxidative phosphorylation gene signatures were down-regulated among responders.Collectively,PD-1 inhibitor showed certain activity on high-risk pulmonary GGO lesions without safety concerns.Such effects were associated with specific T-cell re-distribution,EGF/CTLA-4 cytokine compensation,and regulation of metabolism pathways.展开更多
To the Editor:Over the past few years,the number of cancer survivors has continued to increase,primarily driven by the growing and aging population and the improvements in cancer detection and treatment.More than 16.9...To the Editor:Over the past few years,the number of cancer survivors has continued to increase,primarily driven by the growing and aging population and the improvements in cancer detection and treatment.More than 16.9 million Americans with prior cancers were alive on January 1,2019,and the number of cancer survivors was estimated to reach>22.1 million by January 1,2030.[1]The lifetime risk of individual second primary cancer(SPC)has been confirmed when confronted with such a large amount of cancer survivors.[2]Definition of specific site is shown in supplementary material,http://links.lww.com/CM9/B616.展开更多
Dear Editor,In recent years,the incidence of multifocal lung cancer is increasing,called multiple primary lung cancer(MPLC).Synchronous MPLC(sMPLC)is defined by multiple malignant lesions occurring at the same time.1 ...Dear Editor,In recent years,the incidence of multifocal lung cancer is increasing,called multiple primary lung cancer(MPLC).Synchronous MPLC(sMPLC)is defined by multiple malignant lesions occurring at the same time.1 In clinical practice,it was always extremely difficult to remove all lesions simultaneously for sMPLC patients.However,unresected GGO lesions after primary surgery frequently caught the risk of progression.展开更多
基金China National Science Foundation(Grant No.82022048,82373121)the Science and Technology Planning Project of Guangzhou(grant number 202206080013)the National Key Research&Development Programme(grant numbers 2022YFC2505100).
文摘Immune checkpoint inhibitors targeting the programmed cell death-1(PD-1)protein significantly improve survival in patients with advanced non-small-cell lung cancer(NSCLC),but its impact on early-stage ground-glass opacity(GGO)lesions remains unclear.This is a single-arm,phase II trial(NCT04026841)using Simon’s optimal two-stage design,of which 4 doses of sintilimab(200 mg per 3 weeks)were administrated in 36 enrolled multiple primary lung cancer(MPLC)patients with persistent high-risk(Lung-RADS category 4 or had progressed within 6 months)GGOs.The primary endpoint was objective response rate(ORR).T/B/NK-cell subpopulations,TCR-seq,cytokines,exosomal RNA,and multiplexed immunohistochemistry(mIHC)were monitored and compared between responders and non-responders.Finally,two intent-to-treat(ITT)lesions(pure-GGO or GGO-predominant)showed responses(ORR:5.6%,2/36),and no patients had progressive disease(PD).No grade 3-5 TRAEs occurred.The total response rate considering two ITT lesions and three non-intent-to-treat(NITT)lesions(pure-solid or solid-predominant)was 13.9%(5/36).The proportion of CD8^(+)T cells,the ratio of CD8^(+)/CD4^(+),and the TCR clonality value were significantly higher in the peripheral blood of responders before treatment and decreased over time.Correspondingly,the mIHC analysis showed more CD8^(+)T cells infiltrated in responders.Besides,responders’cytokine concentrations of EGF and CTLA-4 increased during treatment.The exosomal expression of fatty acid metabolism and oxidative phosphorylation gene signatures were down-regulated among responders.Collectively,PD-1 inhibitor showed certain activity on high-risk pulmonary GGO lesions without safety concerns.Such effects were associated with specific T-cell re-distribution,EGF/CTLA-4 cytokine compensation,and regulation of metabolism pathways.
基金China National Science Foundation(No.81871893)Key Project of Guangzhou Scientific Research Project(No.201804020030)
文摘To the Editor:Over the past few years,the number of cancer survivors has continued to increase,primarily driven by the growing and aging population and the improvements in cancer detection and treatment.More than 16.9 million Americans with prior cancers were alive on January 1,2019,and the number of cancer survivors was estimated to reach>22.1 million by January 1,2030.[1]The lifetime risk of individual second primary cancer(SPC)has been confirmed when confronted with such a large amount of cancer survivors.[2]Definition of specific site is shown in supplementary material,http://links.lww.com/CM9/B616.
基金supported by the following funding:The grant 2016YFC0905400 from the National Key R&D Program of ChinaChina National Science Foundation(Grant No.81871893&No.81501996)+2 种基金Key Project of Guangzhou Scientific Research Project(Grant No.201804020030)High-level university construction project of Guangzhou medical university(Grant No.20182737,201721007,201715907,2017160107)National key R&D Program(Grant No.2017YFC0907903&2017YFC0112704).
文摘Dear Editor,In recent years,the incidence of multifocal lung cancer is increasing,called multiple primary lung cancer(MPLC).Synchronous MPLC(sMPLC)is defined by multiple malignant lesions occurring at the same time.1 In clinical practice,it was always extremely difficult to remove all lesions simultaneously for sMPLC patients.However,unresected GGO lesions after primary surgery frequently caught the risk of progression.
